188 related articles for article (PubMed ID: 37932012)
1. ATR inhibition induces synthetic lethality in mismatch repair-deficient cells and augments immunotherapy.
Wang M; Ran X; Leung W; Kawale A; Saxena S; Ouyang J; Patel PS; Dong Y; Yin T; Shu J; Manguso RT; Lan L; Wang XF; Lawrence MS; Zou L
Genes Dev; 2023 Oct; 37(19-20):929-943. PubMed ID: 37932012
[TBL] [Abstract][Full Text] [Related]
2. Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer.
Liu C; Wang X; Qin W; Tu J; Li C; Zhao W; Ma L; Liu B; Qiu H; Yuan X
Cancer Commun (Lond); 2023 Apr; 43(4):435-454. PubMed ID: 36855844
[TBL] [Abstract][Full Text] [Related]
3. WEE1 inhibitor and ataxia telangiectasia and RAD3-related inhibitor trigger stimulator of interferon gene-dependent immune response and enhance tumor treatment efficacy through programmed death-ligand 1 blockade.
Wu X; Kang X; Zhang X; Xie W; Su Y; Liu X; Guo L; Guo E; Li F; Hu D; Qin X; Fu Y; Peng W; Jia J; Wang C
Cancer Sci; 2021 Nov; 112(11):4444-4456. PubMed ID: 34382294
[TBL] [Abstract][Full Text] [Related]
4. The schedule of ATR inhibitor AZD6738 can potentiate or abolish antitumor immune responses to radiotherapy.
Vendetti FP; Pandya P; Clump DA; Schamus-Haynes S; Tavakoli M; diMayorca M; Islam NM; Chang J; Delgoffe GM; Beumer JH; Bakkenist CJ
JCI Insight; 2023 Feb; 8(4):. PubMed ID: 36810257
[TBL] [Abstract][Full Text] [Related]
5. BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors.
Fu Y; Yang B; Cui Y; Hu X; Li X; Lu F; Qin T; Zhang L; Hu Z; Guo E; Fan J; Xiao R; Li W; Qin X; Hu D; Peng W; Liu J; Wang B; Mills GB; Chen G; Sun C
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37072347
[TBL] [Abstract][Full Text] [Related]
6. A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments.
Mohni KN; Thompson PS; Luzwick JW; Glick GG; Pendleton CS; Lehmann BD; Pietenpol JA; Cortez D
PLoS One; 2015; 10(5):e0125482. PubMed ID: 25965342
[TBL] [Abstract][Full Text] [Related]
7. Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer.
Ramchander NC; Ryan NAJ; Walker TDJ; Harries L; Bolton J; Bosse T; Evans DG; Crosbie EJ
Front Immunol; 2019; 10():3023. PubMed ID: 31998307
[TBL] [Abstract][Full Text] [Related]
8. Selective vulnerability of ARID1A deficient colon cancer cells to combined radiation and ATR-inhibitor therapy.
Xu S; Sak A; Niedermaier B; Erol YB; Groneberg M; Mladenov E; Kang M; Iliakis G; Stuschke M
Front Oncol; 2022; 12():999626. PubMed ID: 36249060
[TBL] [Abstract][Full Text] [Related]
9. Detection of coding microsatellite frameshift mutations in DNA mismatch repair-deficient mouse intestinal tumors.
Woerner SM; Tosti E; Yuan YP; Kloor M; Bork P; Edelmann W; Gebert J
Mol Carcinog; 2015 Nov; 54(11):1376-86. PubMed ID: 25213383
[TBL] [Abstract][Full Text] [Related]
10. Targeting DNA polymerase β elicits synthetic lethality with mismatch repair deficiency in acute lymphoblastic leukemia.
Teng JY; Yang DP; Tang C; Fang HS; Sun HY; Xiang YN; Li XM; Yang F; Xia RX; Fan F; Liu J; Yu J; Hu JC; Li BS; Li H; Meng FL; Duan CW; Zhou BS
Leukemia; 2023 Jun; 37(6):1204-1215. PubMed ID: 37095208
[TBL] [Abstract][Full Text] [Related]
11. ATR-Chk1 activation mitigates replication stress caused by mismatch repair-dependent processing of DNA damage.
Gupta D; Lin B; Cowan A; Heinen CD
Proc Natl Acad Sci U S A; 2018 Feb; 115(7):1523-1528. PubMed ID: 29378956
[TBL] [Abstract][Full Text] [Related]
12. Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response.
Mandal R; Samstein RM; Lee KW; Havel JJ; Wang H; Krishna C; Sabio EY; Makarov V; Kuo F; Blecua P; Ramaswamy AT; Durham JN; Bartlett B; Ma X; Srivastava R; Middha S; Zehir A; Hechtman JF; Morris LG; Weinhold N; Riaz N; Le DT; Diaz LA; Chan TA
Science; 2019 May; 364(6439):485-491. PubMed ID: 31048490
[TBL] [Abstract][Full Text] [Related]
13. Exploiting DNA mismatch repair deficiency as a therapeutic strategy.
Guillotin D; Martin SA
Exp Cell Res; 2014 Nov; 329(1):110-5. PubMed ID: 25017099
[TBL] [Abstract][Full Text] [Related]
14. Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models.
Dunlop CR; Wallez Y; Johnson TI; Bernaldo de Quirós Fernández S; Durant ST; Cadogan EB; Lau A; Richards FM; Jodrell DI
Br J Cancer; 2020 Oct; 123(9):1424-1436. PubMed ID: 32741974
[TBL] [Abstract][Full Text] [Related]
15. Mismatch repair deficiency in ovarian cancer -- molecular characteristics and clinical implications.
Xiao X; Melton DW; Gourley C
Gynecol Oncol; 2014 Feb; 132(2):506-12. PubMed ID: 24333356
[TBL] [Abstract][Full Text] [Related]
16. Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S Phase.
Buisson R; Boisvert JL; Benes CH; Zou L
Mol Cell; 2015 Sep; 59(6):1011-24. PubMed ID: 26365377
[TBL] [Abstract][Full Text] [Related]
17. Can evaluation of mismatch repair defect and TILs increase the number of triple-negative breast cancer patients eligible for immunotherapy?
Özcan D; Lade-Keller J; Tramm T
Pathol Res Pract; 2021 Oct; 226():153606. PubMed ID: 34530255
[TBL] [Abstract][Full Text] [Related]
18. Could Mismatch Repair Status Serve as a Biomarker for Immunotherapy in Endometrial Carcinoma?
Vagios S; Doulgeraki T; Giannikaki E; Kavoura E; Papadimitriou C; Gakiopoulou H; Pavlakis K
Anticancer Res; 2020 Mar; 40(3):1669-1676. PubMed ID: 32132073
[TBL] [Abstract][Full Text] [Related]
19. ATR inhibition reverses the resistance of homologous recombination deficient MGMT
El Touny LH; Hose C; Connelly J; Harris E; Monks A; Dull AB; Wilsker DF; Hollingshead MG; Gottholm-Ahalt M; Alcoser SY; Mullendore ME; Parchment RE; Doroshow JH; Teicher BA; Rapisarda A
Oncotarget; 2021 Oct; 12(21):2114-2130. PubMed ID: 34676045
[TBL] [Abstract][Full Text] [Related]
20. Loss of Cyclin C or CDK8 provides ATR inhibitor resistance by suppressing transcription-associated replication stress.
Lloyd RL; Urban V; Muñoz-Martínez F; Ayestaran I; Thomas JC; de Renty C; O'Connor MJ; Forment JV; Galanty Y; Jackson SP
Nucleic Acids Res; 2021 Sep; 49(15):8665-8683. PubMed ID: 34329458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]